Sionna Therapeutics (SION) Cash & Equivalents (2024 - 2026)

Sionna Therapeutics has disclosed Cash & Equivalents across 3 years of filings, most recently posting $63.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $63.3 million, down 23.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.3 million (down 23.42% YoY), and the FY2025 annual result was $58.5 million, up 54.68% from the prior year.
• Cash & Equivalents came in at $63.3 million for Q1 2026 at Sionna Therapeutics, up from $58.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $82.8 million in Q1 2024 to a low of $35.7 million in Q3 2024.
• The 3-year median for Cash & Equivalents is $50.8 million (2025), against an average of $55.2 million.
• Across the five-year window, Cash & Equivalents jumped 54.68% in 2025 and dropped 23.42% in 2026, its largest moves.
• Sionna Therapeutics' Cash & Equivalents stood at $37.8 million in 2024, then soared by 54.68% to $58.5 million in 2025, then climbed by 8.34% to $63.3 million in 2026.
• The last three Cash & Equivalents figures came in at $63.3 million (Q1 2026), $58.5 million (Q4 2025), and $50.8 million (Q3 2025), per Business Quant data.